Sugi Predict

Sugi Predict / Compounds / Valine

Valine

Valine

SCHEMBL111113

CC(C)[C@H](N)C(=O)O.c1cc[nH]c1

nearest known ligand 0.65

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SLC7A5 Q01650 2/20 0.65
▸ SLC1A3 P43003 6/20 0.38
▸ SLC1A2 P43004 6/20 0.38
▸ SLC1A1 P43005 5/20 0.38
▸ SLC15A1 P46059 1/20 0.36
▸ MEN1 O00255 1/20 0.34
▸ CYP1A2 P05177 1/20 0.34
▸ CYP2D6 P10635 1/20 0.34
▸ CYP2C9 P11712 1/20 0.34
▸ CYP2C19 P33261 1/20 0.34
▸ KMT2A Q03164 1/20 0.34
▸ GRIK1 P39086 2/20 0.33
▸ GRIA2 P42262 2/20 0.33
▸ GRIA4 P48058 2/20 0.33
▸ GRIK3 Q13003 2/20 0.33
▸ GRIK5 Q16478 2/20 0.33
▸ GRIA1 P42261 1/20 0.33
▸ GRIK2 Q13002 1/20 0.33
▸ USP2 O75604 1/20 0.33
▸ SLCO1B1 Q9Y6L6 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Valine SCHEMBL27662657 1.00 SLC7A5 (0.65) SLC7A5SLC1A3SLC1A2SLC1A1SLC15A1
Valine SCHEMBL4582565 0.86 SLC7A5 (0.88) SLC7A5SLC1A3SLC1A2SLC1A1SLC15A1
Valine SCHEMBL28052598 0.86 SLC7A5 (0.88) SLC7A5SLC1A3SLC1A2SLC1A1SLC15A1
Alanine SCHEMBL389574 0.84 SLC7A5 (0.41) SLC7A5SLC1A3SLC1A2SLC1A1GRIK1
Alanine SCHEMBL1577981 0.84 SLC7A5 (0.41) SLC7A5SLC1A3SLC1A2SLC1A1GRIK1
Alanine SCHEMBL9653878 0.82 SLC7A5 (0.39) SLC7A5SLC1A3SLC1A2SLC1A1GRIK1
Isoleucine SCHEMBL5774034 0.82 DPP4 (0.43) SLC7A5DPP4
Valine SCHEMBL27817390 0.81 SLC7A5 (0.79) SLC7A5SLC1A3SLC1A2SLC1A1SLC15A1
Valine SCHEMBL27597271 0.81 SLC7A5 (0.79) SLC7A5SLC1A3SLC1A2SLC1A1SLC15A1
Valine SCHEMBL1813972 0.81 SLC7A5 (1.00) SLC7A5SLC1A3SLC1A2SLC1A1USP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1683 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1713780-B1 NOVEL INHIBITORS OF GLUTAMINYL CYCLASE PROBIODRUG AG (DE) 2012-01-18 — — EP claimed
US-20110294735-A1 MECHANISM OF NEUROMEDIN U ACTION AND USES THEREOF MERCK SHARP & DOHME CORP. (US) 2011-12-01 — — US claimed
JP-4806628-B2 — — 2011-11-02 — — JP claimed
EP-2352512-A1 MECHANISM OF NEUROMEDIN U ACTION AND USES THEREOF Merck Sharp & Dohme Corp. (US) 2011-08-10 — — EP claimed
US-20110091429-A1 Methods for Enhancing Stem Cell Engraftment During Transplantation NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2011-04-21 — — US claimed
EP-1911756-B9 Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto ARENA PHARM INC (US) 2010-05-26 — — EP claimed
WO-2010053830-A1 MECHANISM OF NEUROMEDIN U ACTION AND USES THEREOF MERCK SHARP & DOHME CORP. (US) 2010-05-14 — — WO claimed
EP-1620091-B1 INHIBITORS OF GLUTAMINYL CYCLASE PROBIODRUG AG (DE) 2010-03-31 — — EP claimed
US-7655684-B2 1-(Urea-, thiourea- and cyanoguanidine-methylene)benzyl)imidaoles, treatment of neuronal disorders, especially Alzheimer's disease, Down Syndrome, Parkinson's disease and Huntington's disease PROBIODRUG AG (DE) 2010-02-02 — — US claimed
WO-2009152186-A1 METHODS FOR ENHANCING CELL THERAPY EFFICACY INCLUDING TREATMENT WITH CD26 PEPTIDASE INHIBITORS AMERICAN STEM CELL, INC. (US) 2009-12-17 — — WO claimed
EP-1713780-A2 NOVEL INHIBITORS OF GLUTAMINYL CYCLASE Probiodrug AG (DE) 2006-10-25 — — EP claimed
WO-2006099244-A1 COMBINATION THERAPY FOR ENDOTHELIAL DYSFUNCTION, ANGINA AND DIABETES HONG KONG NITRIC OXIDE LIMITED (CN) 2006-09-21 — — WO claimed
US-20060205727-A1 Combination therapy for endothelial dysfunction, angina and diabetes HONG KONG NITRIC OXIDE LIMITED (HK) 2006-09-14 — — US claimed
WO-2006086727-A2 TREATING DIABETES WITH GLUCAGON-LIKE PEPTIDE-1 SECRETAGOGUES ENTELOS, INC. (US) 2006-08-17 — — WO claimed
EP-1620091-A2 INHIBITORS OF GLUTAMINYL CYCLASE Probiodrug AG (DE) 2006-02-01 — — EP claimed
US-20050215573-A1 Novel inhibitors of glutaminyl cyclase PROBIODRUG AG 2005-09-29 — — US claimed
WO-2005075436-A2 NOVEL INHIBITORS OF GLUTAMINYL CYCLASE PROBIODRUG AG (DE) 2005-08-18 — — WO claimed
US-20040247574-A1 Methods for enhancing stem cell engraftment during transplantation NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2004-12-09 — — US claimed
WO-2004098591-A2 INHIBITORS OF GLUTAMINYL CYCLASE AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISEASES PROBIODRUG AG (DE) 2004-11-18 — — WO claimed
US-20040224875-A1 Inhibitors of glutaminyl cyclase PROBIODRUG AG (DE) 2004-11-11 — — US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040224875-A1 Inhibitors of glutaminyl cyclase GLS2, GLS, GLUL SLC7A5 1151/4885SLC1A3 38/4885SLC1A2 10/4885
US-20050215573-A1 Novel inhibitors of glutaminyl cyclase GLS2, GLS, GLUL SLC7A5 929/4885SLC1A3 25/4885SLC1A2 9/4885
US-20060205727-A1 Combination therapy for endothelial dysfunction, angina and diabetes DPP4, PRKCSH, PC SLC7A5 1417/4885SLC1A3 3138/4885SLC1A2 3032/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.